Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00486278 · ClinicalTrials.gov registry record · Phase 2
Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00486278 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 51 participants.
The verdict
NCT00486278, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
This trial is conducted in Africa, Asia, Europe, Japan, and North and South America. The aim of this trial is to evaluate the safety and efficacy of activated recombinant human factor VII analogue (vatreptocog alfa (activated)) in haemophilia patients with inhibitors.
Interventions
- DRUG vatreptacog alfa (activated)
- DRUG eptacog alfa (activated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00486278
The ClinicalTrials.gov registry entry for NCT00486278 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which vatreptacog alfa (activated) is the first listed.
NCT00486278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00486278 about?
NCT00486278 is a clinical study titled "Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds". This trial is conducted in Africa, Asia, Europe, Japan, and North and South America. The aim of this trial is to evaluate the safety and efficacy of activated recombinant human factor VII analogue (vatreptocog alfa (activated)) in haemophilia patients with inhibitors.
What is the current status of trial NCT00486278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2007-06. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00486278?
The interventions under investigation include: vatreptacog alfa (activated) (DRUG), eptacog alfa (activated) (DRUG).
Who is sponsoring clinical trial NCT00486278?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.